| Literature DB >> 30610500 |
Caroline Apra1,2,3, Chloé Dumot4,5, Pierre Bourdillon6,4, Isabelle Pelissou-Guyotat4,5.
Abstract
Surgery is the only therapeutic option for cerebral cavernous malformations (CCM) and is proposed, whenever possible, after haemorrhagic events, neurological symptoms, or epilepsy, radiosurgery being a controversial alternative in some cases. However, there is no treatment for non-accessible lesions, such as brainstem CCM, multiple CCM, or those located in functional areas. Propranolol, a non-selective beta-blocker used as first-line treatment for infantile haemangiomas, has proved spectacularly effective in a few cases of adult patients with CCM. We herein review the histological, in vitro data and clinical findings that support the idea of propranolol as a potential treatment for CCM. Since one retrospective study has not been conclusive, we support the idea that prospective trials are necessary.Entities:
Keywords: Beta-blocker; Cavernomas; Cavernous angiomas; Cavernous haemangiomas; Cavernous malformations
Mesh:
Substances:
Year: 2019 PMID: 30610500 DOI: 10.1007/s10143-018-01074-0
Source DB: PubMed Journal: Neurosurg Rev ISSN: 0344-5607 Impact factor: 3.042